Extended Data Fig. 7. Data supporting Fig. 3.

a, Total VB5, CoA, acetyl-CoA levels, and VB5 labelling data from main Fig. 3a. Graphed metabolites measured using LC-MS/MS. Replicate samples (○). Mean (bars). SEM (error bars); n = 3 biological replicates. *significant difference from treatment marked (†), one-way ANOVA with Tukey’s test, (p<alpha 0.05). b, Fractional abundance (M+4/total) of labelled CoA species in main Fig. 3b. Replicate samples (○). Mean (bars). SEM (error bars); n = 3 biological replicates. c, siRNA-mediated knockdown of PANK4 in SUM159 cells with ¹³C₃¹⁵N₁-VB5 labelling (3 hours) in the presence of 10% fetal bovine serum. Protein immunoblots probed with indicated antibodies (left); size markers in kD (right). Graphed metabolites measured by LC-MS/MS. Replicate samples (○). Mean (bars). SEM (error bars); n = 3 biological replicates. *significant difference from treatment marked (†), two-tailed student’s t-test, (p<alpha 0.05). d, siRNA-mediated knockdown of PANK4 in MDA-MB-468 cells with ¹³C₃¹⁵N₁-VB5 labelling (3 h). Cells were grown in media with dialysed fetal bovine serum (FBS). Protein immunoblots probed with indicated antibodies (left); size markers in kD (right). Graphed metabolites measured by LC-MS/MS. Replicate samples (○). Mean (bars). SEM (error bars); n = 3 biological replicates. *significant difference from treatment marked (†), two-tailed student’s t-test, (p<alpha 0.05). e, Steady state ¹³C₃¹⁵N₁-VB5 labelling (5 μM, 3–5 days) in SUM159 cells grown in RPMI and 10% FBS which contain ~5 μM unlabelled VB5. Graphed metabolites measured by LC-MS/MS and expressed as fractional abundance of labelled metabolites (M+4/total). Replicate samples (○). Mean (bars). SEM (error bars); n = 3 biological replicates.